These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11449623

  • 1. [Possibilities of vaccination against HPV infections in cervix carcinoma].
    Gissmann L.
    Zentralbl Gynakol; 2001 May; 123(5):299-301. PubMed ID: 11449623
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R.
    Intervirology; 1996 May; 39(1-2):54-61. PubMed ID: 8957670
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [Abstract] [Full Text] [Related]

  • 7. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
    Cornelison TL.
    Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
    [Abstract] [Full Text] [Related]

  • 8. Synthesis, properties and applications of papillomavirus-like particles.
    Sapp M, Volpers C, Streeck RE.
    Intervirology; 1996 Sep; 39(1-2):49-53. PubMed ID: 8957669
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [HPV vaccine in the last trial phase. Is cervix carcinoma soon to be eradicated?].
    Grubert TA.
    MMW Fortschr Med; 2003 Jun 26; 145(26):34-7. PubMed ID: 12916335
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J.
    Gene Ther; 2000 Nov 26; 7(21):1859-66. PubMed ID: 11110419
    [Abstract] [Full Text] [Related]

  • 13. [Biology of the papillomavirus infections: V. Vaccine developments].
    Seilles E, Riethmuller D, Mougin C.
    Ann Biol Clin (Paris); 1999 Nov 26; 57(5):517-24. PubMed ID: 10518053
    [Abstract] [Full Text] [Related]

  • 14. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.
    Ling M, Kanayama M, Roden R, Wu TC.
    J Biomed Sci; 2000 Nov 26; 7(5):341-56. PubMed ID: 10971133
    [Abstract] [Full Text] [Related]

  • 15. Preventive vaccines for cervical cancer.
    Wheeler CM.
    Salud Publica Mex; 1997 Nov 26; 39(4):283-7. PubMed ID: 9337561
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The use of vaccines in the prevention and treatment of cervical cancer.
    Davidson EJ, Kitchener HC, Stern PL.
    Clin Oncol (R Coll Radiol); 2002 Jun 26; 14(3):193-200. PubMed ID: 12109821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.